Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Sep 24, 2026
Why Is Stitch Fix (SFIX) Stock Down -24.11% Today?

Why Is Stitch Fix (SFIX) Stock Down -24.11% Today?

Key Takeaways

  • Shares plunged roughly 24.11% to about $2.14, down from a prior close of $2.82.
  • Primary catalyst: weaker-than-expected revenue guidance for fiscal 2027 and the first quarter, issued alongside fourth-quarter results.
  • Secondary drivers: a shrinking active client base, higher customer acquisition costs, and planned increases in advertising and AI investment.
  • Broader context: management cited a "more challenging consumer environment" pressuring discretionary retail spending.
  • What traders are watching: whether client growth resumes and whether AI-driven engagement translates into measurable revenue gains.

Opening Summary

Stitch Fix, Inc. (SFIX), the San Francisco-based online personal styling and apparel retailer, is seeing a sharp selloff in Thursday's session. Shares are down approximately 24.11% to around $2.14, compared with the previous session's closing price of $2.82. The decline extends a post-earnings slide that began after the company reported fourth-quarter and full-year fiscal 2026 results following Wednesday's close, with investors focusing on guidance that points to potential revenue contraction ahead.

Weak Guidance Overwhelms Otherwise Improving Results

The immediate trigger for the selloff was Stitch Fix's forward outlook. For fiscal 2027, the company guided to revenue of $1.31 billion to $1.36 billion, below the consensus expectation of roughly $1.40 billion to $1.41 billion. At the midpoint, that range implies revenue could decline slightly from the $1.35 billion the company posted in fiscal 2026, a reversal of the growth narrative that management had emphasized throughout the past year.

First-quarter fiscal 2027 guidance was similarly disappointing. The company projected revenue of $323 million to $328 million, well short of the roughly $352 million to $355 million analysts had anticipated. Adjusted EBITDA guidance also came in below expectations, at $3 million to $6 million for the quarter and $27 million to $42 million for the full year. Management attributed the lower profitability outlook to planned reinvestment in advertising and artificial-intelligence initiatives.

Mixed Fourth-Quarter Results

The quarterly results themselves were mixed. Stitch Fix reported a net loss of $0.02 per share on revenue of $324.4 million, with the per-share result beating the roughly $0.06 loss Wall Street expected while revenue came in slightly light of estimates. Revenue grew 4.2% year over year, marking a sixth consecutive quarter of positive growth, and revenue per active client reached a record $592.

However, the company's active client base slipped 1.4% year over year to approximately 2.28 million, underscoring a persistent challenge: recent growth has been driven by higher spending per existing client rather than by expanding the customer base. Management noted that higher customer acquisition costs and macroeconomic pressure on discretionary spending have weighed on the ability to add clients cost-effectively.

A "More Challenging Consumer Environment"

Beyond the numbers, commentary from leadership framed the softer outlook as a function of the broader consumer backdrop. The company said its full-year forecast "reflects a more challenging consumer environment and a lower active client starting point," factors it expects will temper revenue growth. Management also flagged two temporary drags on the first quarter: a timing shift that pulled some Fix shipments into the fourth quarter, and an unintended change to the post-checkout offer flow in August that limited how many clients could request another Fix. The company said both issues have been corrected.

Market Context and Trading Activity

Trading activity has been elevated as investors reposition following the guidance disappointment, consistent with a high-volatility name reacting to a significant fundamental update. The decline has pushed SFIX below its prior 52-week low, deepening losses for a stock that had already fallen sharply over the trailing year. The move reflects investor concern that near-term headwinds, including higher customer acquisition costs and deliberate investment spending, may outweigh the company's longer-term strategic progress in AI-powered styling and assortment expansion.

What Comes Next for SFIX

Investors will be watching whether Stitch Fix can return to year-over-year active client growth and whether its investments in advertising and artificial intelligence, including its Vision AI try-on tool, convert into sustainable revenue gains. The company has pointed to improved retention and record revenue per active client as evidence its transformation is working, but the market is now demanding proof that top-line growth can resume. Risks include ongoing consumer pressure on discretionary spending, elevated acquisition costs, and execution uncertainty around the company's growth initiatives.

Trending AI Robots

For traders seeking a data-driven edge, Tickeron's Trending AI Robots page offers a curated view of AI-powered trading bots. Tickeron provides hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this section. Bots vary by strategy, timeframe, performance metrics, and traded symbols, allowing users to explore approaches aligned with their own objectives. Discover which strategies are currently leading the market.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: SFIX

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


SFIX's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for SFIX turned positive on September 14, 2026. Looking at past instances where SFIX's MACD turned positive, the stock continued to rise in 38 of 42 cases over the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where SFIX's RSI Indicator exited the oversold zone, 28 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 56 of 64 cases where SFIX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.

Following a +5.28% 3-day Advance, the price is estimated to grow further. Considering data from situations where SFIX advanced for three days, in 216 of 260 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SFIX as a result. In 81 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SFIX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

The Aroon Indicator for SFIX entered a downward trend on September 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.919) is normal, around the industry mean (3.360). P/E Ratio (101.960) is within average values for comparable stocks, (154.528). Projected Growth (PEG Ratio) (0.300) is also within normal values, averaging (0.513). Dividend Yield (0.000) settles around the average of (0.013) among similar stocks. P/S Ratio (0.292) is also within normal values, averaging (0.652).

The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. SFIX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SFIX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.

Notable companies

The most notable companies in this group are TJX Companies (NYSE:TJX), lululemon athletica (NASDAQ:LULU), Gap Inc (The) (NYSE:GAP), Abercrombie & Fitch Co (NYSE:ANF), Stitch Fix (NASDAQ:SFIX).

Industry description

Companies in the apparel and/or footwear retail industry sell clothing, accessories and footwear, for different age groups and genders. The industry’s product categories could range from basics, such as underwear, to luxury items. Some retailers source items from wholesalers or an apparel brand to sell in their stores; some others are licensed to make and market their own retail goods under particular brands. Several companies outsource production of clothing to developing/emerging economies where labor costs are relatively inexpensive. Apparel retail is often influenced by fashion trends, and many companies feel the need to adapt to what’s “in vogue” to retain customers and attract new ones. A major disruption in this industry has been the burgeoning trend in digital shopping – to compete with rapidly growing e-commerce, even traditional retail players are upping the ante on their online platforms. Much of the products’ performance in apparel/footwear retail is cyclical, i.e., economic boom times encourage consumer spending, while recessions induce thriftiness among people. Some large-cap U.S. apparel/footwear retail companies include TJX Companies Inc., Ross Stores, Inc., Lululemon Athletica Inc. and Burlington Stores, Inc.

Market Cap

The average market capitalization across the Apparel/Footwear Retail Industry is 8.69B. The market cap for tickers in the group ranges from 131.6K to 190.27B. IDEXY holds the highest valuation in this group at 190.27B. The lowest valued company is DESTQ at 131.6K.

High and low price notable news

The average weekly price growth across all stocks in the Apparel/Footwear Retail Industry was -2%. For the same Industry, the average monthly price growth was -11%, and the average quarterly price growth was -7%. DBGI experienced the highest price growth at 39%, while REF experienced the biggest fall at -21%.

Volume

The average weekly volume growth across all stocks in the Apparel/Footwear Retail Industry was -18%. For the same stocks of the Industry, the average monthly volume growth was 13% and the average quarterly volume growth was -14%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 43
P/E Growth Rating: 57
Price Growth Rating: 63
SMR Rating: 64
Profit Risk Rating: 88
Seasonality Score: -20 (-100 ... +100)
View a ticker or compare two or three
SFIX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of subscription-based personal shopping and delivery services for women's clothing

Industry ApparelFootwearRetail

Industry
Apparel Or Footwear Retail
Address
1 Montgomery Street
Phone
+1 415 882-7765
Employees
4165
Web
https://www.stitchfix.com
Interact to see
Advertisement
BAK shares fell roughly 11% in the latest trading session, marking a sharp single-day drop for the Brazilian petrochemical producer The decline comes amid persistent concerns about high leverage, a weaker credit profile, and soft petrochemical margins in a challenging macro environment for chemicals​
INSM shares are surging approximately +10% in premarket trading on Monday, March 23, 2026, from a prior close of $136.00, placing the premarket price near $149.60. The primary catalyst is the release of positive topline results from the Phase 3 ENCORE trial of ARIKAYCE® in patients with newly diagnosed or recurrent MAC (Mycobacterium avium complex) lung disease — a readout Insmed had flagged as expected in "March or April 2026".
CF shares are trading approximately -6% lower in Monday's premarket session, dropping from a Friday close of $124.90 to approximately $117.41. Primary catalyst: President Trump announced a five-day pause on strikes against Iranian energy infrastructure following "very good" diplomatic signals, triggering a sharp unwind of the geopolitical risk premium embedded in fertilizer stocks.
APGE shares surged approximately 16% in premarket trading on March 23, 2026, after the company announced positive 52-week data from Part A of its Phase 2 APEX clinical trial. The primary catalyst is a highly anticipated clinical readout showing that zumilokibart (APG777) delivered durable and deepening responses in patients with moderate-to-severe atopic dermatitis at both every 3-month and 6-month dosing intervals.
Shares of VALN are plummeting approximately 35% in Monday's session, from a Friday close of $10.66 to roughly $6.93, in heavy volume trading. The primary catalyst is the release of Phase 3 VALOR trial topline results for Valneva's Lyme disease vaccine candidate, co-developed with PFE (Pfizer) — results that showed strong clinical efficacy but failed to meet the pre-determined statistical criterion for the primary endpoint.
AXTI is surging approximately +11.00% in Monday's session, trading near $60.21, up from a prior closing price of $54.24. The move extends the stock's post-earnings rally that began last Thursday when shares jumped more than 19% following AXT's Q4 2025 results.
Tower Semiconductor (TSEM) shares are surging approximately +10% intraday on Monday, March 23, trading around $180, up from the previous close of $163.63 on March 20, 2026. The primary catalyst is the opening day of APEC 2026 in San Antonio, Texas, where Tower Semiconductor is presenting its newly unveiled Gen3 BCD power management platform designed to address escalating AI data center power demands.
CD is indicated down about 17% in premarket trading after the latest completed session, pointing to a sharp negative market reaction heading into the open. The stock’s weakness comes against a backdrop of lingering uncertainty following its privatization and delisting process from Nasdaq, which has left limited liquidity and a thinner news flow around the name.
SEDG is indicated down roughly 9% in premarket trading, following a strong advance in the prior regular session. The pullback comes after shares rallied on optimism around new product launches and an analyst upgrade, leaving the stock vulnerable to profit-taking and volatility.
NTGR shares surged approximately 11% in premarket trading on March 24, 2026, building on a roughly 20% overnight jump in the prior session. The primary catalyst is a landmark Federal Communications Commission (FCC) ruling that prohibits all imports of consumer routers manufactured overseas, citing national security concerns.
ANNA is surging approximately +20.00% in Tuesday's premarket session, rebounding sharply from Monday's -22.84% decline. The primary catalyst remains the ongoing U.S.-Iran military conflict, which disrupted Qatari LNG exports and drove European benchmark natural gas prices to multi-year highs.
Concentrix Corporation (CNXC) shares are falling approximately 11% in Tuesday's premarket session after the company released its fiscal Q1 2026 earnings report before market open. Adjusted diluted EPS came in at $2.61, missing the Wall Street consensus estimate of approximately $2.64.
Shares of Karyopharm Therapeutics (KPTI) are trading approximately 12% lower in Tuesday's premarket session, with the previous close at $7.63. The primary catalyst is the March 24 release of topline Phase 3 SENTRY trial data, in which the company met only one of two co-primary endpoints.
IBRX shares are down approximately 23% in Tuesday's session, trading near $7.24 after closing at $9.40 on Monday, March 23. The sharp decline follows an 11%+ surge in the prior session, with profit-taking and valuation pressure cited as primary triggers.
Shares of Circle Internet Group (CRCL) are down approximately 9% in Tuesday morning trading, extending a pullback from recent multi-month highs above $126. The primary catalyst appears to be a broad crypto-sector risk-off wave, with Bitcoin sliding below $69,000 and the Fear & Greed Index dropping to extreme fear territory.
ALM shares are indicated down about 11% in early Tuesday trading after closing the prior session at $16.93. The move comes after a powerful multi‑month rally that took the stock from below $3 to an intraday high of $22.55 earlier in March, leaving it vulnerable to profit-taking and volatility.​
LUNR shares are indicated down about 7% in Tuesday premarket trading after closing the last regular session at $20.31. The pullback follows a powerful rally driven by strong 2026 revenue guidance of $900 million–$1 billion and upbeat analyst commentary, including price target hikes and buy ratings.
MAZE shares are trading approximately 27% lower in premarket on March 25, 2026, after the company reported its highly anticipated Phase 2 HORIZON trial topline data for lead drug candidate MZE829. The catalyst is a dual announcement: Phase 2 clinical data for MZE829 in APOL1-mediated kidney disease (AMKD) alongside Q4 and full-year 2025 financial results.
ARM shares surged approximately +10% in premarket trading on March 25, 2026, hitting $148.6 from a prior close of approximately $135. The primary catalyst is Arm's historic strategic pivot: the company announced it will begin selling its own self-developed AGI CPU chips, breaking its decades-long "IP licensing only" business model.
Shares of Enliven Therapeutics (ELVN) are surging approximately +15% in premarket trading on March 25, 2026, driven by renewed investor enthusiasm around the company's advancing clinical program for ELVN-001 in chronic myeloid leukemia (CML). The stock's prior closing price on March 24, 2026 was $31.15, placing the premarket indicated price near $35.82.